U.S. FDA approves Takeda’s Alunbrig (brigatinib) as a first-line treatment option for patients diagnosed with rare and serious form of lung cance

Takeda

22 May 2020 - Long-term results from the Phase 3 ALTA 1L trial established Alunbrig as a superior first-line treatment compared to crizotinib for people with ALK+ metastatic non-small cell lung cancer, including those with brain metastases.

Takeda today announced that the U.S. FDA approved Alunbrig (brigatinib) for adult patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.

This approval expands Alunbrig’s current indication to include the first-line setting.

Read Takeda press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , US